The cancer drug Enhertu showed promising results in a clinical trial, significantly delaying tumor growth in women with metastatic breast cancer. The makers of Enhertu, Daiichi Sankyo and AstraZeneca, believe this new data could change the standard of care for hormone receptor-positive, metastatic breast cancer. Medical oncologists are impressed with the efficacy of Enhertu, calling it the most potent drug ever developed for breast cancer. While there are side effects to manage, the data suggests a new treatment option for patients with breast tumors expressing even small amounts of HER2 protein. This breakthrough may reshape how physicians approach treating this type of breast cancer.
Source link
At ASCO, Astra Zeneca reports strong data for breast cancer drug
